Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Arrowhead PharmaceuticalsArrowhead Pharmaceuticals(US:ARWR) Businesswire·2026-01-06 12:30

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. announced interim results from two Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7, investigational RNA interference therapeutics aimed at treating obesity, showing significant reductions in key health measures [1] Group 1: Clinical Trial Results - The preliminary results indicate meaningful reductions in visceral fat, total fat, and liver measurements, highlighting the potential effectiveness of Arrowhead's new approach to obesity treatment [1]

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition - Reportify